Details for New Drug Application (NDA): 208078
✉ Email this page to a colleague
NDA 208078 describes FIRDAPSE, which is a drug marketed by Catalyst Pharms and is included in one NDA. It is available from one supplier. There are six patents protecting this drug. Additional details are available on the FIRDAPSE profile page.
The generic ingredient in FIRDAPSE is amifampridine phosphate. One supplier is listed for this compound. Additional details are available on the amifampridine phosphate profile page.
The generic ingredient in FIRDAPSE is amifampridine phosphate. One supplier is listed for this compound. Additional details are available on the amifampridine phosphate profile page.
Summary for 208078
| Tradename: | FIRDAPSE |
| Applicant: | Catalyst Pharms |
| Ingredient: | amifampridine phosphate |
| Patents: | 6 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 208078
Generic Entry Date for 208078*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 208078
| Mechanism of Action | Potassium Channel Antagonists |
Suppliers and Packaging for NDA: 208078
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| FIRDAPSE | amifampridine phosphate | TABLET;ORAL | 208078 | NDA | Catalyst Pharmaceuticals, Inc. | 69616-211 | 69616-211-03 | 240 TABLET in 1 BOTTLE, PLASTIC (69616-211-03) |
| FIRDAPSE | amifampridine phosphate | TABLET;ORAL | 208078 | NDA | Catalyst Pharmaceuticals, Inc. | 69616-211 | 69616-211-06 | 12 BLISTER PACK in 1 CARTON (69616-211-06) / 10 TABLET in 1 BLISTER PACK (69616-211-04) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 10MG BASE | ||||
| Approval Date: | Nov 28, 2018 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Sep 29, 2025 | ||||||||
| Regulatory Exclusivity Use: | NEW PATIENT POPULATION | ||||||||
| Regulatory Exclusivity Expiration: | Nov 28, 2025 | ||||||||
| Regulatory Exclusivity Use: | TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME (LEMS) | ||||||||
| Patent: | ⤷ Subscribe | Patent Expiration: | Feb 25, 2037 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
